Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home

User menu

  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

ASHNR American Society of Functional Neuroradiology ASHNR American Society of Pediatric Neuroradiology ASSR
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Accepted Manuscripts
    • Article Preview
    • Past Issue Archive
    • Video Articles
    • AJNR Case Collection
    • Case of the Week Archive
    • Case of the Month Archive
    • Classic Case Archive
  • Special Collections
    • AJNR Awards
    • Low-Field MRI
    • Alzheimer Disease
    • ASNR Foundation Special Collection
    • Photon-Counting CT
    • View All
  • Multimedia
    • AJNR Podcasts
    • AJNR SCANtastic
    • Trainee Corner
    • MRI Safety Corner
    • Imaging Protocols
  • For Authors
    • Submit a Manuscript
    • Submit a Video Article
    • Submit an eLetter to the Editor/Response
    • Manuscript Submission Guidelines
    • Statistical Tips
    • Fast Publishing of Accepted Manuscripts
    • Graphical Abstract Preparation
    • Imaging Protocol Submission
    • Author Policies
  • About Us
    • About AJNR
    • Editorial Board
    • Editorial Board Alumni
  • More
    • Become a Reviewer/Academy of Reviewers
    • Subscribers
    • Permissions
    • Alerts
    • Feedback
    • Advertisers
    • ASNR Home
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds

AJNR Awards, New Junior Editors, and more. Read the latest AJNR updates

Research ArticleBrain

Dynamic Contrast-enhanced T2*-weighted MR Imaging of Recurrent Malignant Gliomas Treated with Thalidomide and Carboplatin

Soonmee Cha, Edmond A. Knopp, Glyn Johnson, Andrew Litt, Jon Glass, Michael L. Gruber, Stanley Lu and David Zagzag
American Journal of Neuroradiology May 2000, 21 (5) 881-890;
Soonmee Cha
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Edmond A. Knopp
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Glyn Johnson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Litt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jon Glass
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael L. Gruber
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stanley Lu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Zagzag
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • fig 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    fig 1.

    Case 12: 58-year-old man with GBM treated with carboplatin and thalidomide, without concomitant steroid therapy.

    A–C, Postcontrast T1-weighted images. At the start of therapy, an irregularly enhancing mass is seen in the left parietooccipital region (A). At 4-month follow-up, there is mild interval increase in contrast enhancement (B). At 8-month follow-up, a new area of abnormal contrast enhancement is seen in the splenium of the corpus callosum (arrow) as well as lateral periatrial and ventricular involvement (C).

    D–F, Corresponding color overlay images. At the start of therapy, a focal area of hyperperfusion (arrow) is seen in the lateral aspect of the left parietooccipital tumor (D). At 4-month follow-up, there is interval decrease in the perfusion abnormality in the same region (arrow) (E). At 8-month follow-up, almost complete resolution of the perfusion abnormality is noted in the left parietooccipital lobe (arrow). There is no abnormal perfusion corresponding to the contrast enhancement within the splenium of the corpus callosum. Although conventional imaging findings are consistent with tumor progression, a lack of perfusion abnormality suggests otherwise. The patient was clinically stable at 12- and 16-month follow-up examinations (F).

  • fig 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    fig 2.

    Case 3: 36-year-old man with bifrontal GBM treated with carboplatin and thalidomide, without concomitant steroid therapy.

    A–C, Postcontrast T1-weighted images. At the start of therapy, a heterogeneous, irregularly enhancing right frontal GBM with areas of necrosis extends into the contralateral frontal lobe (A). At 3-month follow-up, there is a decrease in contrast enhancement within the bifrontal tumor (B). At 7-month follow-up, there is further decrease in contrast enhancement (C).

    D–F, Corresponding color overlay images. At the start of therapy, a focal area of hyperperfusion is seen in the medial aspect of the right frontal tumor (D). At 3-month follow-up, there is an interval decrease in the perfusion abnormality in the right medial frontal lobe tumor (E). At 7-month follow-up, a new focus of hyperperfusion is seen in the left medial frontal lobe (arrow) without corresponding abnormality on conventional T1-weighted image (F).

  • fig 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    fig 3.

    Case 6: 46-year-old-man with left medial frontal anaplastic oligoastrocytoma treated with carboplatin and thalidomide, without concomitant steroid therapy.

    A–C, Postcontrast T1-weighted images. At the start of therapy, a solid enhancing mass is seen in the left medial frontal lobe (A). At 3-month follow-up, there is a slight increase in contrast enhancement (B). At 8-month follow-up, there is a less solid and more linear pattern of enhancement (C).

    D–F, Corresponding color overlay images. At the start of therapy, there is minimal hyperperfusion, corresponding to the left medial frontal enhancing tumor (D). At 3-month follow-up, there is an increase in hyperperfusion (E). At 8-month follow-up, there is further progression of hyperperfusion, corresponding well with patient's deteriorating clinical status (F).

  • fig 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    fig 4.

    Serial rCBV measurements at each follow-up examination for all patients receiving thalidomide and carboplatin. The interval between each examination varied from 2 to 3 months. The first examination was at the start of the therapy and the fifth examination was at the 12-month follow-up. The decrease in rCBV measurements between the initial and first follow-up examination was statistically significant (P = .0014)

  • fig 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    fig 5.

    Serial rCBV measurements for patients receiving carboplatin only. There was no statistically significant change in rCBV during the course of therapy

  • fig 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    fig 6.

    Serial rCBV measurements between the relapsed and the stable groups show a statistically significant difference in rCBV (P = .0161) at the 12-month follow-up (ie, the fifth examination), where the relapsed group had higher values than the stable group

  • fig 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    fig 7.

    Azocarmine stain from a patient (case 7) with recurrent GBM who was treated with carboplatin and thalidomide shows multilayered reduplication of the basal lamina around a microvessel (solid straight arrow). Around this vascular channel, there are several mono- or multinucleated tumor cells (open arrows). Adjacent is a tumor microcyst (curved arrow)

Tables

  • Figures
  • Table1

    Diagnosis and outcome in the 18 patients with recurrent malignant glioma who received both thalidomide and carboplatin

PreviousNext
Back to top

In this issue

American Journal of Neuroradiology
Vol. 21, Issue 5
1 May 2000
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Dynamic Contrast-enhanced T2*-weighted MR Imaging of Recurrent Malignant Gliomas Treated with Thalidomide and Carboplatin
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Cite this article
Soonmee Cha, Edmond A. Knopp, Glyn Johnson, Andrew Litt, Jon Glass, Michael L. Gruber, Stanley Lu, David Zagzag
Dynamic Contrast-enhanced T2*-weighted MR Imaging of Recurrent Malignant Gliomas Treated with Thalidomide and Carboplatin
American Journal of Neuroradiology May 2000, 21 (5) 881-890;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
0 Responses
Respond to this article
Share
Bookmark this article
Dynamic Contrast-enhanced T2*-weighted MR Imaging of Recurrent Malignant Gliomas Treated with Thalidomide and Carboplatin
Soonmee Cha, Edmond A. Knopp, Glyn Johnson, Andrew Litt, Jon Glass, Michael L. Gruber, Stanley Lu, David Zagzag
American Journal of Neuroradiology May 2000, 21 (5) 881-890;
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Conclusion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • Responses
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Lessons From Anti-Vascular Endothelial Growth Factor and Anti-Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma
  • The Role of Preload and Leakage Correction in Gadolinium-Based Cerebral Blood Volume Estimation Determined by Comparison with MION as a Criterion Standard
  • Imaging biomarkers of angiogenesis and the microvascular environment in cerebral tumours
  • Specific biomarkers of receptors, pathways of inhibition and targeted therapies: clinical applications
  • Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors
  • Dynamic Magnetic Resonance Perfusion Imaging of Brain Tumors
  • MRI for assessing antivascular cancer treatments
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Evaluating the Effects of White Matter Multiple Sclerosis Lesions on the Volume Estimation of 6 Brain Tissue Segmentation Methods
  • Quiet PROPELLER MRI Techniques Match the Quality of Conventional PROPELLER Brain Imaging Techniques
  • Predictors of Reperfusion in Patients with Acute Ischemic Stroke
Show more Brain

Similar Articles

Advertisement

Indexed Content

  • Current Issue
  • Accepted Manuscripts
  • Article Preview
  • Past Issues
  • Editorials
  • Editor's Choice
  • Fellows' Journal Club
  • Letters to the Editor
  • Video Articles

Cases

  • Case Collection
  • Archive - Case of the Week
  • Archive - Case of the Month
  • Archive - Classic Case

More from AJNR

  • Trainee Corner
  • Imaging Protocols
  • MRI Safety Corner
  • Book Reviews

Multimedia

  • AJNR Podcasts
  • AJNR Scantastics

Resources

  • Turnaround Time
  • Submit a Manuscript
  • Submit a Video Article
  • Submit an eLetter to the Editor/Response
  • Manuscript Submission Guidelines
  • Statistical Tips
  • Fast Publishing of Accepted Manuscripts
  • Graphical Abstract Preparation
  • Imaging Protocol Submission
  • Evidence-Based Medicine Level Guide
  • Publishing Checklists
  • Author Policies
  • Become a Reviewer/Academy of Reviewers
  • News and Updates

About Us

  • About AJNR
  • Editorial Board
  • Editorial Board Alumni
  • Alerts
  • Permissions
  • Not an AJNR Subscriber? Join Now
  • Advertise with Us
  • Librarian Resources
  • Feedback
  • Terms and Conditions
  • AJNR Editorial Board Alumni

American Society of Neuroradiology

  • Not an ASNR Member? Join Now

© 2025 by the American Society of Neuroradiology All rights, including for text and data mining, AI training, and similar technologies, are reserved.
Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire